Complexo Hospitalario Universitario De Vigo
- Address
- Estrada Clara Campoamor N 341, 36312 Vigo, Spain
Neurology – Multiple Sclerosis and Neurodegenerative Disorders
At the Complexo Hospitalario Universitario De Vigo the neurology department leads trials aimed at evaluating new disease‑modifying therapies for multiple sclerosis and related neuro‑inflammatory conditions, seeking to slow disability progression and improve quality of life.
- Relapsing forms of multiple sclerosis
- Primary and secondary progressive multiple sclerosis
- Upper limb spasticity after stroke or traumatic brain injury
- Biomarker‑driven treatment selection for first‑episode psychosis
The neurology program encompasses 63 active trials with 65 investigators, emphasizing innovative mechanisms, patient‑centered outcomes, and long‑term safety monitoring across neurodegenerative diseases.
Oncology – Solid Tumor Therapeutics
The site hosts a broad oncology program that tests targeted agents, immunotherapies and combination regimens in cancers such as breast cancer, ovarian cancer, non‑small cell lung cancer and prostate cancer, with the goal of improving survival and response rates.
- HER2‑positive and triple‑negative breast cancer
- BRCA‑mutated ovarian and pancreatic cancers
- Resectable and advanced non‑small cell lung cancer
- High‑risk prostate cancer with androgen deprivation therapy
Oncology investigators collaborate across surgical, medical and radiation specialties, contributing to the overall portfolio of 63 clinical trials aimed at advancing curative and maintenance strategies.
Cardiovascular and Metabolic Disease Research
Clinical studies at the hospital address acute and chronic heart conditions, including myocardial infarction, heart failure, hypertrophic cardiomyopathy and hypertension, as well as metabolic disorders like type 2 diabetes, aiming to reduce mortality and improve cardiac function.
- Post‑myocardial infarction left ventricular dysfunction
- Symptomatic hypertrophic cardiomyopathy
- Takotsubo syndrome treatment strategies
- Cardiovascular risk reduction with lipid‑lowering agents
The cardiovascular research team leverages advanced imaging and biomarker analysis to support 63 trials, integrating cardiology expertise with metabolic disease management.
Autoimmune and Systemic Inflammatory Disorders
Investigators explore novel biologics and small molecules for systemic autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis and Sjögren’s syndrome, focusing on disease activity control and organ protection.
- Active and refractory lupus nephritis
- Early systemic lupus erythematosus
- Psoriatic arthritis with skin and joint involvement
- Sjögren’s syndrome with interstitial lung disease
Long‑term safety extensions and patient‑reported outcomes are integral to the 63‑trial portfolio, supporting a comprehensive approach to autoimmune disease management.
Infectious Diseases and Immune System Research
The research portfolio includes trials targeting bacterial infections, viral hepatitis and emerging pathogens, evaluating optimized antibiotic regimens and antiviral therapies to enhance cure rates and limit resistance.
- Pseudomonas aeruginosa bacteremia short‑course antibiotics
- Chronic hepatitis B virus infection therapies
- COVID‑19 therapeutic interventions
- Enterococcal bacteremia treatment duration studies
Leveraging the analytical and diagnostic equipment area, investigators contribute to the overall 63 clinical trials, advancing precision medicine for infectious and immune‑mediated diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 17 therapeutic areas and 15 of 237 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 232 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
- 1Janssen Cilag International3active
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International9trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Complexo Hospitalario Universitario De Vigo
lock Showing 1 of 100 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 237 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 6 | Unknown | 2018-01-10 | 2025-12-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.